We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Portable CRISPR-Based Molecular Technology Brings Highly Accurate Diagnostics to Point of Need

By LabMedica International staff writers
Posted on 20 Jun 2025

A comprehensive solution for point-of-care diagnostics harnesses the power of CRISPR-Cas for extreme accuracy in an onsite setting. More...

Scope Biosciences B.V.’s (Wageningen, Netherlands) scopeDx is a next-gen CRISPR-based molecular diagnostics platform that delivers ultra-precise, single-nucleotide detection in a format that is portable and field-ready without proprietary hardware or centralized labs. The scopeDx platform uses proprietary type III CRISPR-Cas technology to detect nucleic acid sequences, dramatically enhancing the ability to detect genetic material with ease, speed and accuracy, for use in molecular diagnostics in infectious diseases, genotyping, and other applications. scopeDx combines isothermal LAMP amplification with a novel type III CRISPR-Cas technology to detect target nucleic acid material. This brings together rapid isothermal amplification characteristics with extreme specificity due to the CRISPR-Cas module, and leads to a high-performing diagnostic solution.

The robust scopeDx workflow includes a quick, hardware-free, sample extraction step with minimal reagent handling steps to improve ease of use & reliability. scopeDx is suitable for the detection of both RNA and DNA, in under 25 minutes, and is sensitive enough to detect the smallest amount of genetic material. It is capable of detecting single-nucleotide variations if desired, while its isothermal nature allows for simple, intuitive, and portable readout with minimal training. Multiple samples (extraction and controls) are amplified and measured in real-time, for specific and fast confirmation of the presence of the pathogen of choice. The scopeDx technology allows diagnostics to be performed closer to the source — in the field, at the point of care and contributes to faster and broader access to reliable testing, especially in areas where centralized laboratories are not available.

Designed to offer an unparalleled "sample to answer" solution, scopeDx ensures rapid, accurate, and accessible diagnostic services in various settings, including hospitals and remote clinics. The versatility of scopeDx stems from its capability to perform highly specific on-site testing, facilitating rapid and efficient diagnostic procedures. This becomes especially pivotal in scenarios requiring immediate results, minimizing the delay between testing and vital treatment initiation. By empowering healthcare settings with accurate and reliable diagnostic tests, scopeDx bridges the gap between immediate healthcare needs and specialized diagnostics.

“We’re scaling up, building out our platform and getting ready to meet real-world diagnostic challenges head-on,” said Niek Savelkoul, CEO and founder of ScopeBio.

Related Links:
Scope Biosciences B.V. 


Gold Member
Troponin T QC
Troponin T Quality Control
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Modular Hemostasis Automation Solution
CN Track
New
Silver Member
Autoimmune Hepatitis Test
LKM-1-Ab ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: Micrograph showing the distribution of misfolded proteins in myeloma cells (Photo courtesy of Helmholtz Munich)

Novel Method Tracks Cancer Treatment in Cells Without Dyes or Labels

Multiple myeloma is a blood cancer that affects plasma cells in the bone marrow, leading to abnormal protein production, weakened immunity, and organ damage. Traditional methods for evaluating myeloma... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.